AstraZeneca PLC (AZN) stock
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca net income
Net income is the profit left for shareholders after every expense, interest and tax.
For fiscal 2025 it was $10.23B, up 45.3% from the year before. Over ten years it grew 13.7% a year on average. The highest annual figure on record is $10.23B in fiscal 2025.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.23B | +45.3% |
| FY2024 | Dec 31, 2024 | $7.04B | +18.1% |
| FY2023 | Dec 31, 2023 | $5.96B | +81.1% |
| FY2022 | Dec 31, 2022 | $3.29B | +2835.7% |
| FY2021 | Dec 31, 2021 | $112.00M | -96.5% |
| FY2020 | Dec 31, 2020 | $3.20B | +139.4% |
| FY2019 | Dec 31, 2019 | $1.34B | -38.1% |
| FY2018 | Dec 31, 2018 | $2.16B | -28.2% |
| FY2017 | Dec 31, 2017 | $3.00B | -14.2% |
| FY2016 | Dec 31, 2016 | $3.50B | +23.9% |
| FY2015 | Dec 31, 2015 | $2.83B | – |
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $2.51B | +596.4% |
| Q2 FY2025 | Jun 30, 2025 | $2.45B | +345.5% |
| Q2 FY2024 | Jun 30, 2024 | $1.93B | +154.9% |
| Q2 FY2023 | Jun 30, 2023 | $1.82B | +1298.5% |
| Q2 FY2022 | Jun 30, 2022 | $360.00M | +2.9% |
| Q2 FY2021 | Jun 30, 2021 | $550.00M | +15.3% |
| Q2 FY2020 | Jun 30, 2020 | $756.00M | – |
| Q2 FY2019 | Jun 30, 2019 | $130.00M | – |
| Q2 FY2018 | Jun 30, 2018 | $350.00M | – |
| Q2 FY2017 | Jun 30, 2017 | $477.00M | – |
See a number that looks wrong?